DISEASE CHARACTERISTICS:

• Histologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube cancer

  • Disease has recurred or is resistant to prior treatment with at least 1 platinum-based regimen and meets ≥ 1 of the following criteria:

    • Platinum-refractory disease, defined as progression during the first 6 courses of first-line therapy with a platinum-based regimen
    • Platinum-resistant disease, defined as progression within 6 months after completing first-line platinum-based chemotherapy
    • Platinum-sensitive disease, defined as progression > 6 months after completing first-line platinum-based chemotherapy
    • Disease that has progressed while receiving or recurred within 6 months after completing platinum-based second-line therapy
  • Patients who have experienced failure of a second line therapy > 6 months after completing treatment or who have received more than 2 prior chemotherapy regimens are not eligible
• No diagnosis of borderline or low malignant potential epithelial carcinoma

• Measurable disease per RECIST criteria, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques or ≥ 10 mm by spiral CT scan

  • Patients without measurable disease may enter with elevated CA 125 levels if previously normal or stable CA 125 levels are documented after the completion of the prior chemotherapy regimen

PATIENT CHARACTERISTICS:

• GOG performance status 0-2
• Absolute neutrophil count ≥ 1.5 x 10^9/L
• Platelet count ≥ 100 x 10^9/L
• Serum creatinine ≤ 1.5 mg/dL
• Total bilirubin < 1.2 mg/dL
• AST and ALT ≤ 2 times upper limit of normal (ULN) (≤ 5 times ULN if hepatic metastases are present)
• LVEF normal
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective double-method contraception beginning at least 28 days before study treatment
• Peripheral neuropathy ≤ grade 2 (CTCAE v 3.0)
• No HIV positivity
• No infectious hepatitis A, B, or C positivity
• Progression-free of prior malignancies for at least 5 years, except currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast
• Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to aspirin may use warfarin or low molecular weight heparin)
• No serious medical condition, laboratory abnormality, or psychiatric illness that, in the opinion of the investigator, would prevent the patient from signing the consent form
• No history of myocardial infarction, congestive heart failure, or arrhythmia requiring medication
• No history of uncontrolled hypertension
• No history of systolic or diastolic dysfunction
• No EKG evidence of ventricular hypertrophy, conduction abnormality, or serious arrhythmia
• No deep vein thromboembolism within the past 6 months
• No history of thrombocytopenia or bleeding disorders
• No condition, including the presence of laboratory abnormalities, that places the patient at unacceptable risk if she were to participate in the study or confounds the ability to interpret data from the study
• No known hypersensitivity reaction > grade 2 to thalidomide or structurally related compounds
• No development of erythema nodosum, if characterized by a desquamating rash while taking thalidomide or similar drugs
• No uncontrolled hyper- or hypocalcemia, hyper- or hypoglycosemia, or hyper- or hypothyroidism

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• Patients who are taking a stable or decreasing dose of concurrent systemic steroids during the study must agree to also take low-dose acetylsalicylic acid (aspirin) and/or other platelet-active, antithrombotic medication during and for 30 days after study treatment
• At least 28 days since prior cancer therapy, including chemotherapy, hormonal therapy, and surgery
• At least 2 weeks since prior thalidomide or structurally related compounds, radiotherapy, or biologic response modifiers
• More than 28 days since prior experimental drug or therapy
• No prior lenalidomide or pegylated liposomal doxorubicin hydrochloride
• No other concurrent anticancer agents or treatments
• No other concurrent chemotherapies, immunotherapies, or investigational agents